Abstract:Background: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare and progressive disease caused by mutations in the TYMP gene, which encodes the enzyme thymidine phosphorylase (TP). This results in a systemic accumulation of nucleosides and mitochondrial toxicity. AAV-based liver-directed gene therapy has shown efficacy in preclinical studies, but it has limitations such as a decline of transgene expression long-term. We propose that gene editing can circumvent some of these problems.Methods: We performed a preclinical study in the murine model of MNGIE to assess that the coordinated delivery of CRISPR/Cas9 and a TYMP cDNA caused the efficient integration of a TYMP transgene into introns of the Tymp and Alb loci in hepatocytes. CRISPR/Cas9 was delivered either as mRNA using nanoparticles or in AAV2/8 viral vectors; the latter were also used to package the TYMP cDNA. We assessed the efficient integration of the templates into the liver cells, and monitored the nucleoside levels in plasma to detect the biochemical correction.Findings: The best results were obtained using lipid nanoparticles. The consistent and stable nucleoside reduction observed correlated with the presence of TYMP mRNA and functional enzyme in the liver cells. In mice with an edited Alb locus, the transgene produced a hybrid Alb-hTP protein that was secreted, with high levels of TP activity in plasma.Interpretation: Liver-directed gene editing is a feasible approach to achieve the long-term biochemical correction of the disease, with several advantages over previous methods.Funding Information: This project was made possible with financial support from the Instituto de Salud Carlos III/FEDER (grant PI15/00172) and from MINECO/FEDER (grant RTI2018-094734-B-C22). The support of the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya, through SGR 2017 1559 grant, is also acknowledged.Declaration of Interests: S.H.Y.F. and Y.K.T. are employees of Acuitas Therapeutics, a company focused on the development of lipid nanoparticle delivery systems for nucleic-acid-based drugs. RM was the recipient of personal fees associated with advisory tasks and of financial support from Modis Therapeutics for research outside the submitted work. RM also holds a patent “Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes” (PCT/US16/038110), with royalties paid to Modis Therapeutics.INCOMPLETEEthics Approval Statement: All animal procedures were performed in accordance with European recommendations and were approved by our institutional ethics committee (Comitè Ètic d’Experimentació Animal).

Mitochondrial adenine base editing of mouse somatic tissues via adeno-associated viral delivery

In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue

Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice Via Adeno-Associated Viruses

Engineered mitochondrial A-to-G editors with enhanced efficiency and targeting scope

Adenine transversion editors enable precise, efficient A•T-to-C•G base editing in mammalian cells and embryos

Adenine Base Editing in vivo with a Single Adeno-Associated Virus Vector

Mitochondrial DNA editing in mice with DddA-TALE fusion deaminases

Precision genome editing using cytosine and adenine base editors in mammalian cells

Engineering TALE-linked deaminases to facilitate precision adenine base editing in mitochondrial DNA

Tools for editing the mammalian mitochondrial genome

Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy

Engineering a Precise Adenine Base Editor with Minimal Bystander Editing.

Adenine base editor‐based correction of the cardiac pathogenic Lmna c.1621C > T mutation in murine hearts

Directed evolution of adenine base editors with increased activity and therapeutic application

Engineering precise adenine base editor with infinitesimal rates of bystander mutations and off-target editing

Strand-selective base editing of human mitochondrial DNA using mitoBEs

Design and application of the transformer base editor in mammalian cells and mice

Unconstrained Precision Mitochondrial Genome Editing with αDdCBEs

Human Cell Based Directed Evolution of Adenine Base Editors with Improved Efficiency

Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope

Preclinical Assessment of a Gene Editing Approach in a Mouse Model of MNGIE